• Publications
  • Influence
Tadalafil Therapy for Pulmonary Arterial Hypertension
TLDR
In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening.
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
TLDR
Results from a single-center, uncontrolled study suggest that long-term, continuously infused epoprostenol therapy can produce hemodynamic and symptomatic responses in patients with connective tissue disease who have severe pulmonary hypertension that is refractory to conventional medical therapy.
Ambrisentan therapy for pulmonary arterial hypertension.
TLDR
Ambrisentan appears to improve exercise capacity, symptoms, and hemodynamics in patients with PAH, and the incidence and severity of liver enzyme abnormalities appear to be low.
Sitaxsentan therapy for pulmonary arterial hypertension.
TLDR
Although the 300-mg group increased peak VO(2) compared with placebo (+3.1%, p < 0.01), none of the other endpoints derived from cardiopulmonary exercise testing were met and neither the functional class, cardiac index, and pulmonary vascular resistance improved.
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
TLDR
Treatment with the selective ET(A) receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity.
Beraprost therapy for pulmonary arterial hypertension.
TLDR
These data suggest that beneficial effects may occur during early phases of treatment with beraprost in WHO functional class II or III patients but that this effect attenuates with time.
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.
TLDR
Data from a Phase II study are consistent with imatinib being well tolerated in patients with PAH, and provide proof of concept for further studies evaluating its safety, tolerability, and efficacy in PAH.
Evaluation of new clinical criteria for the diagnosis of infective endocarditis.
TLDR
The Duke criteria are superior to the von Reyn criteria for the clinical diagnosis of IE, predominantly reflecting use of two-dimensional echocardiographic demonstration of valvular vegetations in the Duke schema.
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C
TLDR
This study enhanced understanding of oral treprostinil titration and dosing, which has set the stage for additional studies.
Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.
TLDR
Long-term follow-up of this single-center patient group demonstrated improved long-term survival during epo therapy compared with that in historical control subjects and confirms predicted improved outcomes based on shorter follow- up periods.
...
1
2
3
4
5
...